Dr. Anh Nguyen serves as Chief Medical Officer at Xeris Biopharma Holdings, Inc., a biopharmaceutical company dedicated to developing innovative, ready-to-use formulations of peptide and protein therapeutics for chronic diseases. In this pivotal role, she leads global clinical development, medical affairs, pharmacovigilance, and regulatory strategy, overseeing the advancement of Xeris' proprietary XeriSol and XeriJect technologies. Her leadership has been instrumental in expanding the company's pipeline, including key programs for congenital adrenal hyperplasia, diabetic hypoglycemia, and hypoparathyroidism. With over 25 years of experience in endocrinology and rare diseases, Dr. Nguyen previously served as Chief Medical Officer at Strongbridge Biopharma, which was acquired by Xeris in 2023, and held senior roles at Horizon Therapeutics, where she contributed to the successful FDA approval of Tepezza (teprotumumab) for thyroid eye disease. A board-certified endocrinologist, she earned her MD from the University of Texas Southwestern Medical School, completed her residency in internal medicine at Parkland Memorial Hospital, and her fellowship in endocrinology at the University of Chicago. Her career highlights include leading multiple Phase 3 trials and authoring numerous peer-reviewed publications on endocrine disorders. Dr. Nguyen's patient-centric approach and deep expertise in complex metabolic conditions have driven significant milestones at Xeris, such as the NDA submission for XPB-1120 (levoketoconazole) and ongoing advancements in subcutaneous glucagon formulations. Recognized as a thought leader, she actively engages in industry forums and advisory boards, championing innovative solutions to unmet medical needs.